{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 56 of 74', '23 Appendices', '23.1 Appendix 1 - RECIST Version 1.1', 'For the full RECIST version 1.1, please refer to Eisenhauer E.A. et al.', '46', 'A summary of the criteria applicable for INTERIM is given below.', 'Methods of Assessment', 'Tumour assessments for response and progression require CT scan (or MRI if allergic to', 'intravenous contrast) of thorax/abdomen/pelvis/head or measured by photography', 'including a ruler. The same assessment technique should be used to characterise each', 'identified and reported lesion at baseline and throughout the trial.', 'Measurable Disease', 'Patients will be classified as having measurable or non-measurable disease at baseline', 'and at each imagining assessment.', 'Definition of Measurable Disease lesions', 'Must be accurately measured in at least one dimension (longest diameter in the plane', 'of measurement is to be recorded) with a minimum size of 10 mm by CT scan (CT scan', 'slice thickness no greater than 5 mm; when CT scans have slice thickness >5 mm, the', 'minimum size should be twice the slice thickness).', 'Cutaneous lesions measured by photography including a ruler to indicate size, must be', 'a minimum of 10mm in diameter.', 'Malignant lymph nodes: To be considered pathologically enlarged and measured, a', 'lymph node must be >15 mm in short axis when assessed by CT scan. At baseline and', 'in follow-up, only the short axis will be measured and followed.', 'Definition of Non-measurable lesions', 'Non-measurable lesions are all other lesions, including small lesions (longest diameter', '<10 mm or pathological lymph nodes with 10 to <15 mm short axis), as well as truly', 'non-measurable lesions. Lesions considered truly non-measurable include:', 'leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast', 'disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal', 'organomegaly identified by physical exam that is not measurable by reproducible', 'imaging techniques.', 'Baseline Tumour Assessment', 'The baseline tumour assessment evaluation should be performed within 4 weeks of', 'date of randomisation.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 57 of 74', 'Baseline Documentation of \"Target\" and \"Non-Target\" Lesions', 'Target Lesions', 'All measurable lesions up to a maximum of two lesions per organ and five lesions in', 'total, representative of all involved organs, should be identified as target lesions and', 'recorded and measured at baseline.', 'Target lesions should be selected on the basis of their size (lesions with the longest', 'diameter) and be representative of all involved organs, as well as their suitability for', 'reproducible, repeated measurements.', 'Pathological nodes which are defined as measureable and may be identified as', 'target lesions must meet the criterion of a short axis of >15 mm by CT scan.', 'Sum of the Diameters', 'Sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all', 'target lesions will be calculated and reported as the baseline sum diameters.', 'Non-target Lesions', 'All lesions (or sites of disease) not identified as target lesions, including pathological', 'lymph nodes and all non-measurable lesions, should be identified as non-target lesions', 'and be recorded at baseline. Measurements of these lesions are not required', \"and they should be followed as 'present', 'absent' or in rare cases, 'unequivocal\", \"progression'.\", 'Response Criteria', 'Evaluation of Target Lesions', 'Complete Response (CR):', 'Disappearance of all target lesions. Any pathological lymph nodes (whether target or', 'non-target) must have reduction in short axis to <10 mm.', 'Partial Response (PR):', 'At least a 30% decrease in the sum of diameters of target lesions, taking as reference', 'the baseline sum of diameters.', 'Progressive Disease (PD):', 'At least a 20% increase in the sum of diameters of target lesions, taking as reference', 'the smallest sum on trial (this may include the baseline sum). The sum must also', 'demonstrate an absolute increase of at least 5 mm.', 'Stable Disease (SD):', 'Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.', 'Evaluation of Non-target Lesions', 'Complete Response (CR):', 'Disappearance of all non-target lesions and normalisation of tumour marker levels. All', 'lymph nodes must be non-pathological in size (<10 mm short axis).', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}